PAM
ELVN icon

Panagora Asset Management’s Enliven Therapeutics ELVN Stock Holding History

Panagora Asset Management’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2,863
Closed -$14K – 1458
2022
Q2 		$14K Buy
+2,863
New +$14K ﹤0.01% 1456
2021
Q3 		– Sell
-29
Closed -$1K – 1915
2021
Q2 		$1K Sell
29
-2
-6% -$62 ﹤0.01% 2685
2021
Q1 		$1K Hold
31
– – ﹤0.01% 2764
2020
Q4 		$3K Buy
+31
New +$2.6K ﹤0.01% 2567

Other funds holding ELVN

WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

Panagora Asset Management's ELVN Position: Q3 2022 in Review

Panagora Asset Management sold out of Enliven Therapeutics (ELVN) in Q3 2022, closing a stake of 2,863 shares — an estimated $14K sold.

Panagora Asset Management first reported a position in ELVN in Q4 2020 and held it in 4 quarters. The position peaked at $14K in Q2 2022. 31 funds tracked by Wall St. Rank hold ELVN as of Q3 2022.

  • Panagora Asset Management reported no remaining Enliven Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Panagora Asset Management sold 2,863 Enliven Therapeutics shares in Q3 2022, an estimated $14K.
  • Panagora Asset Management first reported a position in Enliven Therapeutics in Q4 2020 and held it in 4 quarters.
  • Panagora Asset Management's Enliven Therapeutics position peaked at $14K in Q2 2022.
  • 31 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q3 2022.

Based on Panagora Asset Management's 13F filing for Q3 2022, filed 14 Nov 2022.